Table 3.
mRNA expression of DNMTs in different clinical pathological data in HCC patients
| n | Average expression levels of mRNA (95% confidence interval) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||
| DNMT1 | DNMT2 | DNMT3A | DNMT3B | ||||||
|
|
|
|
|
||||||
| Normalized with | Normalized with | Normalized with | Normalized with | ||||||
|
|
|||||||||
| GAPDH | H4 | GAPDH | H4 | GAPDH | H4 | GAPDH | H4 | ||
| Gender | |||||||||
| Male | 35 | 1.15±0.23 | 1.12±0.20 | 0.74±0.15 | 0.73±0.14 | 1.21±0.23 | 1.19±0.21 | 0.54±0.12 | 0.50±0.10 |
| Female | 9 | 1.04±0.24 | 1.04±0.23 | 0.66±0.13 | 0.65±0.13 | 0.99±0.21 | 0.97±0.19 | 0.44±0.11 | 0.43±0.09 |
| Differentiation | |||||||||
| Well | 20 | 0.98±0.19 | 0.95±0.18 | 0.58±0.16 | 0.56±0.15 | 0.96±0.22 | 0.93±0.19 | 0.43±0.12 | 0.41±0.10 |
| Moderate | 18 | 1.20±0.21 | 1.19±0.19 | 0.70±0.15 | 0.68±0.14 | 1.12±0.18 | 1.08±0.17 | 0.46±0.13 | 0.45±0.12 |
| Poor | 6 | 1.23±0.24 | 1.23±0.22 | 0.74±0.16 | 0.72±0.15 | 1.20±0.19 | 1.29±0.18 | 0.50±0.13 | 0.48±0.11 |
| Tumor staging | |||||||||
| I | 20 | 1.08±0.19 | 0.98±0.18 | 0.65±0.15 | 0.64±0.15 | 1.01±0.23 | 0.98±0.21 | 0.44±0.12 | 0.44±0.11 |
| II | 15 | 1.17±0.22 | 1.15±0.19 | 0.69±0.14 | 0.68±0.13 | 1.12±0.21 | 1.08±0.19 | 0.46±0.14 | 0.45±0.13 |
| III | 9 | 1.25±0.24 | 1.23±0.21 | 0.72±0.16 | 0.71±0.15 | 1.18±0.20 | 1.17±0.18 | 0.49±0.14 | 0.48±0.12 |